AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of MAP kinase-activating death domain protein including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into MAP kinase-activating death domain protein therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of MAP kinase-activating death domain protein, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on MAP kinase-activating death domain protein. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of MAP kinase-activating death domain protein. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for MAP kinase-activating death domain protein includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
MAP kinase-activating death domain protein
partner:
Reaxense
upacc:
Q8WXG6
UPID:
MADD_HUMAN
Alternative names:
Differentially expressed in normal and neoplastic cells; Insulinoma glucagonoma clone 20; Rab3 GDP/GTP exchange factor; Rab3 GDP/GTP exchange protein
Alternative UPACC:
Q8WXG6; A8K8S7; B5MEE5; D3DQR4; O15065; O15293; Q15732; Q15741; Q8IWD7; Q8WXG3; Q8WXG4; Q8WXG5; Q8WZ63
Background:
The MAP kinase-activating death domain protein, also known as Rab3 GDP/GTP exchange factor, plays a pivotal role in cellular processes. It regulates small GTPases of the Rab family, crucial for synaptic vesicle exocytosis and vesicle secretion. This protein is involved in synaptic vesicle formation, trafficking at the neuromuscular junction, and up-regulating synaptic exocytosis in central synapses. It also mediates TNFA-mediated activation of the MAPK pathway, including ERK1/2, and may link TNFRSF1A with MAP kinase activation.
Therapeutic significance:
Linked to DEEAH syndrome and a neurodevelopmental disorder with dysmorphic facies, impaired speech, and hypotonia, understanding the role of MAP kinase-activating death domain protein could open doors to potential therapeutic strategies.
